The DRCR Retina Network is undertaking research to develop preventive strategies for diabetic eye disease, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
The DRCR Retina Network is undertaking research to develop preventive strategies for diabetic eye disease. One study is analyzing fenofibrate, which is typically used for cholesterol management, to evaluate how it protects against retinopathy worsening, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
Transcript
What trials are ongoing in the DRCR Retina Network that you want to highlight?
We're very interested in understanding, now that we have good treatments for late-stage disease—in terms of proliferative diabetic retinopathy and diabetic macular edema—how do we develop preventive strategies? One of the studies that is currently up and recruiting is a study looking at fenofibrate use for prevention of retinopathy worsening in early-stage diabetic retinopathy. There are a couple of large cardiovascular studies that have suggested that patients on fenofibrate, which has been typically used for cholesterol management—it's been around for decades, and it's pretty well tolerated, it's cheap, because it's off patent, so it's readily available—these studies have suggested that patients on fenofibrate seem to be protected against retinopathy worsening.
Nonetheless, in general, physicians have not used fenofibrate as first-line treatment for diabetic retinopathy, you know, early-stage disease. We're starting a study that will follow patients for 4 years—randomize them to fenofibrate vs placebo. There are a number of studies that are also ongoing within that study looking at how we look at visual function in these patients through contrast sensitivity, through visual fields, and development of imaging biomarkers of disease progression.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More